Evotec SE, DE0005664809

Evotec stock: Gates Foundation awards $2.9 million grant

Published on 11/16/2026 at 17:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock is in focus after the company extended a Gates Foundation-backed safety research project for another three years. Its platform supports earlier drug screening.

Grant extends safety research

  • Evotec is extending a Gates Foundation-backed project that uses human stem cell models to assess fetal development risks from drug candidates.
  • The funding gives global health researchers continued access to Evotec's screening platform and supports earlier decisions in drug development.
Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec announced on Monday, November 16, that the Gates Foundation awarded the company a new $2.9 million grant for a further three years of early drug safety research. The Financial Times company-announcement page carried the release from Evotec SE.

Human cell models support screening

The grant extends a project launched in 2023 that helps global health researchers identify potential risks to fetal development in novel drug candidates. Evotec's platform combines human induced pluripotent stem cell models with industrial-scale screening capabilities.

The approach is intended to provide human-relevant safety information earlier in drug discovery. That can help researchers decide which candidates should advance toward clinical testing and reduce the risk of costly changes later in development.

Platform remains collaboration asset

Evotec said the initial three-year collaboration screened more than 5,000 compounds across nine grantee programs. The company described the continued funding as support for its broader New Approach Methodologies portfolio, which includes human stem cell-derived models, organoid systems, AI-supported disease modeling and high-throughput screening.

Evotec stock traded at 2.96 euros on Lang & Schwarz at 17:14 CET on Monday, November 16, 2026.

Evotec company details

  • Company: Evotec SE
  • ISIN: DE0005664809
  • Frankfurt ticker: EVT
  • Price: 2.96 euros at Lang & Schwarz, 17:14 CET, November 16, 2026

Broader market conditions can be followed in Current market reports.

More news and analyses on Evotec stock

Disclaimer...
en | DE0005664809 | EVOTEC SE | boerse | 70521802 | bgmi